A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Running, not enrolling · Phase 1 · Has a placebo group

Conditions studied: Congenital Myasthenic Syndrome, CMS

In brief

The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function. After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the double-blinded treatment period. Participants will then enter the follow-up period. After the follow-up period, participants may enrol in the active-treatment period, where they will receive open-label ARGX-119. The full duration of the study is approximately 38 months.

Key facts

Study ID

NCT06436742

Run by

argenx

People needed

15

Starts

2024-09-24

Expected to finish

2028-01-24

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Has genetically confirmed congenital myasthenic syndromes due to mutation of downstream of kinase 7 (DOK7-CMS).
• Participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine) must have been receiving the medication for more than 3 months and agree to remain on a same stable dosing regimen of the same medication until the end of the study.

You may not qualify if…

• Diagnosis of CMS due to mutation of any gene other than DOK7.
• Known medical condition that would interfere with an accurate assessment of CMS, confound the results of the study, or put the patient at undue risk, as assessed by the investigator.
• History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for more than 5 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer.
• Pregnant or lactating state or intention to become pregnant during the study.

Where it is running

• UC Davis Medical Center — Sacramento, California, United States
• Ann and Robert H Lurie Childrens Hospital of Chicago — Chicago, Illinois, United States
• Ottawa Hospital Research Institute - Civic Campus — Ottawa, Canada
• CHU - Hospital de la Timone — Marseille, France
• Group Hospitalier Pitie-Salpetriere — Paris, France
• Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Italy
• Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur) — Valencia, Spain
• Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital — Belfast, United Kingdom
• John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust — Oxford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.